TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
|
|
- Jemima Boone
- 5 years ago
- Views:
Transcription
1 TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
2 Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research Grants Sorin: Consultant
3 Objectives Review current status and evolution of TAVI in Canada Understand the outcomes of TAVI in high risk patients Discuss the evaluation of potential TAVI candidates
4 Aortic Stenosis is Life-threatening and Progresses Rapidly Survival after onset of symptoms is 50% at two years and 20% at five years 1 Surgical intervention [for severe AS] should be performed promptly once even minor symptoms occur 2 1 S.J. Lester et al., The Natural History and Rate of Progression of Aortic Stenosis, Chest C.M. Otto, Valve Disease: Timing of Aortic Valve Surgery, Heart 200 Chart: Ross J Jr, Braunwald E. Aortic Stenosis. Circulation. 1968;38(Suppl 1):
5 Aortic/Mitral Valve Surgery with/without other procedure # cases AVRpl MVRpr MVRpl
6 ACC/AHA INDICATORS FOR AVR Source: Robert O. Bonow et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Valvular Heart Disease). JACC. 2006;e17-e26.
7 SURVIVAL BENEFIT IN SURGICALLY TREATED PATIENT COHORT % Survival Patient survival Years AVR, no Sx AVR, Sx No AVR, no Sx No AVR, Sx Source: Morgan L. Brown et al. The benefits of early valve replacement in asymptomatic patients with severe aortic stenosis. J Thorac Cardiovasc Surg. 2008;135(2):
8 Many patients remain untreated EU United States Sources: 1) B J Bouma et al. To operate or not on elderly patients with aortic stenosis: the decision and its consequences. Heart. 1999;82: ) Bernard Iung et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24: ) Patricia A. Pellikka et al. Outcome of 622 Adults with Asymptomatic, Hemodynamically Significant Aortic Stenosis During Prolonged Follow-Up. Circ. 2005;111: ) Erik Charlson et al. Decision-Making and Outcomes in Severe Symptomatic Aortic Stenosis. J Heart Valve Dis. 2006;15: ) Padmini Varadarajan et al. Clinical Profile and Natural History of 453 nonsurgically Managed Patients With Severe Aortic Stenosis. Ann Thorac Surg. 2006;82: ) David S. Bach et al. Unoperated Patients With Severe Aortic Stenosis. JACC. 2007;50: ) Faud Jan et al. Unoperated Patients With Severe Symptomatic Aortic Stenosis. Circ.2009;120:S753. 8) Benjamin H. Freed et al. Reasons for Nonadherence to Guidelines for Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Potential Solutions. AMJC. 2010;105:
9 How do you decide someone shouldn t have surgery??? 95 years old and Texas tough Courtesy Todd Dewey
10 It s not just about the STS risk score Same age (90) and predicted risk (12%) Frailty Index 7 (Severely frail) 1 (Very fit)
11 Evolution of AS surgery
12
13 Is TAVI better than medical therapy?
14 Rigorous Study Protocols and Management Two Individually Stratified and Powered Cohorts Symptomatic Severe Aortic Stenosis Yes ASSESSMENT: High-Risk AVR Candidate 3,105 Total Patients Screened No Cohort A Total = 1,058 patients Cohort B N = 700 High Risk 2 Parallel Trials: Inoperable N = 358 Individually Powered ASSESSMENT: Transfemoral Access Yes No 1:1 Randomization Not In Study TAVI Transfemoral VS Standard Therapy (Usually BAV) Primary Endpoint: All-Cause Mortality Over Length of Trial (Superiority) Co-Primary Endpoint: Composite of All-Cause Mortality and Repeat Hospitalization (Superiority)
15 20% Absolute Reduction in Mortality at 1 Year 100 All-Cause Mortality Standard Therapy Edwards THV All-Cause Mortality, % at 1 yr = 20.0% NNT = 5.0 pts 50.7% 30.7% Months HR [95% CI] = 0.55 [0.40, 0.74] P (log rank) <.001 Numbers at Risk Edwards THV Standard Therapy
16 How does TAVI compare to surgery?
17 Rigorous Study Protocols and Management Two Individually Stratified and Powered Cohorts Symptomatic Severe Aortic Stenosis Yes ASSESSMENT: High-Risk AVR Candidate 3,105 Total Patients Screened No Cohort A Total = 1,058 patients Cohort B N = 700 High Risk 2 Parallel Trials: Inoperable N = 358 Individually Powered Yes ASSESSMENT: Transfemoral Access No ASSESSMENT: Transfemoral Access High-Risk TF High-Risk TA Yes No 1:1 Randomization 1:1 Randomization 1:1 Randomization Not In Study TAVI Transfemoral VS Surgical AVR TAVI Transapical VS Surgical AVR TAVI Transfemoral VS Standard Therapy (Usually BAV) Primary Endpoint: All-Cause Mortality (1 yr) (Non-inferiority) TA, transapical; TF, transfemoral; BAV, balloon aortic valvuloplasty. Primary Endpoint: All-Cause Mortality Over Length of Trial (Superiority) Co-Primary Endpoint: Composite of All-Cause Mortality and Repeat Hospitalization (Superiority)
18 Primary Endpoint: All-Cause Mortality at 1 Year TAVR AVR HR [95% CI] = 0.93 [0.71, 1.22] P (log rank) = No. at Risk Months TAVR AVR
19 PARTNER trial established: TAVI is better than medical therapy in HIGH risk (STS risk %) patients TAVI shows similar results to AVR in HIGH risk (STS risk 11.8%) patients TAVI is less invasive, recovery is easier Concerns with TAVI High rates of aortic insufficiency Vascular complications Unexpected complications (pacemaker, root rupture )
20 Corevalve PIVOTAL Trial
21 Baseline Demographics 21
22 Non-STS Co-Morbidity, Frailty, Disability 22
23 Primary Endpoint: 1 Year All-cause Mortality ACC 2014 Surgical Transcatheter 19.1% 14.2% 4.5% P = 0.04 for superiority 3.3% 23
24 Corevalve PIVIOTAL 2-Year All-cause Mortality
25 Corevalve PIVIOTAL 2-Year Stroke results 25
26 Other Endpoints 26
27 Echocardiographic Findings 27
28 PIVOTAL Trial First trial to demonstrate lower mortality and stroke with TAVI versus AVR Concerns with TAVI High rates of pacemaker Vascular complications
29 Current Advances Ability to accurately position valve Medtronic Evolut R St. Jude Portico Ability to diminish paravalvular leaks Smaller profile to deal with small and diseased femoral vessels
30 Medtronic Evolut R System Catheter Delivery System 14Fr-equivalent profile Loading System Transcatheter Valve (26, 29 mm) Supra-annular design, optimized sealing
31 Characteristic, % or mean± SD N = 60 Age (years) 82.8 ± 6.1 Women 66.7 Body surface area (m 2 ) 1.7 ± 0.2 Society of Thoracic Surgeons Predicted Risk of Mortality (%) 7.0 ± 3.7 Logistic EuroSCORE I (%) 20.5 ± 12.5 New York Heart Association class III or IV 68.3 Previous CABG 28.3 Any chronic lung disease 43.3 Diabetes 26.7 Peripheral vascular disease 16.7 Atrial fibrillation / atrial flutter 36.7 Frailty 68.3 Pre-existing permanent pacemaker 11.7
32 Safety Event, K-M rates (no. of patients) 30 Days N=60 6 Months N=60 All-cause mortality 0.0 (0) 5.0 (3) Cardiovascular 0.0 (0) 3.3 (2) All stroke 0.0 (0) 1.7 (1) Disabling 0.0 (0) 1.7 (1) Non-disabling 0.0 (0) 0.0 (0) Major vascular complications 8.3 (5) 8.3 (5) Life-threatening or disabling bleeding 5.0 (3) 8.4 (5) Embolization or migration 0.0 (0) 0.0 (0) Endocarditis 0.0 (0) 0.0 (0) Coronary obstruction 0.0 (0) 0.0 (0) Valve thrombosis 0.0 (0) 0.0 (0) Pacemaker* 11.7 (7) 13.4 (8) *Patients with a prior pacemaker included in the denominator.
33 NYHA Class Compared with Baseline, 74.9% Improved at 30 Days and 84.9% at 6 Months Percent of Patients 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 8.3% 60.0% 31.7% Baseline N= % 11.3% 37.3% 50.8% 30 Days N= % 67.9% 6 Months N=53 NYHA I NYHA II NYHA III NYHA IV CoreValve Evolut R CE Study 33
34 CoreValve Evolut R CE Study 34 Paravalvular Regurgitation Percent of Evaluable Echocardiograms 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 6.8% 3.4% 7.4% 57.6% 63.8% 35.6% 32.8% 24 H/ 7 Days N=59 30 Days N= % 57.4% 6 Months N=54 None/Trace Mild Moderate Severe
35 Edwards SAPIEN 3 transcatheter heart valve 2 1 Outer Sealing Skirt Designed to minimise paravalvular leak 3 2 Frame Design Enhanced frame geometry for ultra-low delivery profile High radial strength for circularity and optimal haemodynamics Low frame height respects the cardiac anatomy 1 3 Proven Valve Tissue Optimised leaflet shape Utilises the same bovine pericardial tissue and processes as Edwards surgical valves Carpentier-Edwards ThermaFix* process for anti-calcification * No clinical data are available which evaluate the long-term impact of the Carpentier-Edwards ThermaFix process in patients
36 3.7% 2 4.5% 2 3.5% 2 2.1% 2 Impact of technology and procedure advancement on 30-day mortality rates (KM%) 20% 15% 10% 8.2% 1 6.3% 2 5% 1.6% 2 0% P1A (AVR) P1B (TF) P1A (TF) P2B (TF) P2B XT (TF) S3 EU (TF) S3HR (TF) AVR SAPIEN Valve SAPIEN XT Valve SAPIEN 3 Valve 1. Kodali, S., Transfemoral AVR vs. Surgical Aortic Valve Replacement in High Risk Patients with Severe Aortic Stenosis: Results From The PARTNER Trial. Presented at TVT 2011, June 5, 2011; Vancouver, Canada. 2. Kodali, S., Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients. Presented at ACC 2015, March 15, 2015; San Diego, California.
37 Unprecedented outcomes at 1 year with the SAPIEN 3 valve Paravalvular AR (Paired Analysis) Transfemoral Population None/Trace Mild Moderate Severe 100% 3.2% 3.2% 80% 28.6% 17.5% 60% 40% 68.2% 79.4% 20% 0% 30 Days 1 Year N = 63 N = 63 Incidence of Moderate/Severe Paravalvular AR Remained Low at 1 Year Data on file
38 Increase in 1 year survival rates from the SAPIEN valve to the SAPIEN 3 valve 1 Year KM All-Cause Mortality TF Population SOURCE SOURCE XT SAPIEN 3 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Months 91.6% 85.1% 80.1% Webb J., 1-Year Outcomes from The SAPIEN 3 Trial. Presented at EuroPCR 2015, May 19, 2015; Paris, France.
39 Ultra-low profile SAPIEN 3 system expands treatment possibilities while reducing complications Major Vascular Complications 15.9% 1 Reduction in Major Vascular Complications In Transfemoral Patients 11.3% 1 5.3% 2 4.2% 3 N = 271 N = 282 N = 491 N = 96 PARTNER II Trial Coh B SAPIEN Valve 23/26 mm PARTNER II Trial Coh B SAPIEN XT Valve 23/26 mm PARTNER II Trial SAPIEN 3 Valve 20/23/26/29 mm SAPIEN 3 Trial SAPIEN 3 Valve 23/26/29 mm Sheath Edwards RetroFlex 3 Introducer Sheath Set Edwards Expandable Introducer Sheath Set Edwards esheath Introducer Set Sheath Size 22 / 24F 16 / 18F 14 / 16F Minimum Vessel Access Diameter 7.0 / 8.0 mm 6.0 / 6.5 mm 5.5 / 6.0 mm 1. Data on file, Edwards Lifesciences 2. Kodali S., Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients. Presented at ACC 2015, March 15, 2015; San Diego, California. 3. Webb J., Multicenter Evaluation of a Next-Generation Balloon-Expandable Transcatheter Aortic Valve. JACC, VOL.64,NO.21, pg.2238, 2014
40 Supported by unprecedented outcomes and real world results Edwards SAPIEN transcatheter heart valves are the most widely used transcatheter heart valves worldwide and consistently demonstrate clinical excellence in both trials and real-world experience*: Over 100,000 Patients Treated Worldwide Over 30,000 Patients Treated in Clinical Trials & Registries Treating Patients in Over 65 Countries *As of February 2015
41 Hospital to Hospital OPCC Dr. Paddock/ Dr. Pelletier Cath Severe Aortic Stenosis Acknowledge Referral Surgical Consult Consult Dr Paddock Dr Pelletier Coordinate Assessment Assessment Completed In Hospital or Hostel Local Review Health Canada Presentation Procedure Out of Province Reimbursement Approval
42
43 TAVI NB Heart Centre CANADA Special Access Program 2009 NBHC Oct 2015 Procedure Success 94% # of Patients (6 failed implants) 339 Transfemoral 169 Transapical Alternative Access 96% 200 (6 failed implants) Mean Age 81 ± 8 years Female 55% Procedural Outcomes (30 Day): 30 Day Mortality 10.4% Stroke 2.3% Myocardial Infarction (MI) Hemodialysis 1.2% 2.3% 81 years 51 % 2.0 % (4) 1.5 % (3) 1.5% (3) 0% Vascular Complications (Access-Related) 12.8% 1.0 % (2) 43
44
45 Final Thoughts TAVI IS the real deal Results of TAVI are consistent with Excellence in Hospital and Community Care Major technological advances in 13 years Next focus will be on trials for low risk patients TAVI as a day procedure is coming
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationThe Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationTranscatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis
Transcatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis John Webb MD Director interventional cardiology, St Paul s Hospital McLeod Professor of
More informationEdwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?
Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationTranscatheter Aortic Valve Replacement TAVR
Transcatheter Aortic Valve Replacement TAVR Paul Gordon, MD Associate Prof of Medicine, Brown University Director, Cardiac Catheterization Laboratory The Miriam Hospital Disclosures: none 100 Symptomatic
More informationEstablishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS
Establishing a New Path Forward for Patients With Severe Symptomatic Aortic Stenosis THE PARTNER TRIAL CLINICAL RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T h e Pa
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationAortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More informationTranscatheter Therapies For Aortic Valve Disease. March 2017 Brian Whisenant MD
Transcatheter Therapies For Aortic Valve Disease March 2017 Brian Whisenant MD Introduction I got into this field to protect my turf. I must say, I have come full circle... - Kent W. Jones I got into this
More informationLe TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationDebate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI
Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationPercutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update
Percutaneous Aortic Valve Implantation. Core-Valve and Cribier-Edwards Update T. Lefèvre Natural History of Aortic Stenosois 100 Latent period Survival (%) 80 60 40 20 Symptoms Average Age Death 0 40 50
More informationLOW RISK TAVR. WHAT THE FUTURE HOLDS
LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationAppropriate Use of TAVR - now and in the future. A Surgeon s Perspective. Neil Moat Royal Brompton Hospital, London, UK
Appropriate Use of TAVR - now and in the future A Surgeon s Perspective Neil Moat Royal Brompton Hospital, London, UK Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationTAVI After PARTNER-2 : The Hamilton Approach
TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University
More informationRANDOMISED TRIALS TAVI WITH SAVR STEPHAN WINDECKER AORTIC VALVE DISEASE COMPARING
AORTIC VALVE DISEASE RANDOMISED TRIALS COMPARING TAVI WITH SAVR STEPHAN WINDECKER DEPARTMENT OF CARDIOLOGY SWISS CARDIOVASCULAR CENTER AND CLINICAL TRIALS UNIT BERN BERN UNIVERSITY HOSPITAL, SWITZERLAND
More informationTrans Catheter Aortic Valve Replacement
Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationTAVI: Nouveaux Horizons
TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationTAVI: Present and Future Perspective
TAVI: Present and Future Perspective Igor F. Palacios, M.D. Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School Percutaneous transcatheter
More informationEdwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved
Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio
More informationTAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
More informationAortic stenosis (AS) remains the most common
Sapien Valve: Past, Present, and Future A look at how the Sapien family of valves continues to evolve to treat a range of patients seeking transcatheter aortic valve replacement. BY RAVINDER SINGH RAO,
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationTAVR for low-risk patients in 2017: not so fast.
TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for
More informationTRANSAPICAL AORTIC VALVE REPAIR
TRANSAPICAL AORTIC VALVE REPAIR Mauro ROMANO M.D. Department of Cardio-Vascular Surgery Institut Cardiovasculaire Paris Sud Institut Hospitalier Jacques Cartier MASSY FRANCE romano.mauro@orange.fr Treatment
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationTAVR: Intermediate Risk Patients
TAVR: Intermediate Risk Patients Oscar A. Mendiz.MD.FACC.FSCAI Director Cardiology & Cardiovascular Institute (ICyCC) Chief Interventional Cardiology Department Board of Directors Hospital & Favaloro University
More informationThe SAPIEN 3 TAVI Advantage
Edwards SAPIEN 3 Valve The SAPIEN 3 TAVI Advantage... The SAPIEN 3 TAVI Advantage The clear choice for your patients and your TAVI program Advanced valve and system designed to simplify procedures Consistent
More informationThe Role of TAVI in high-risk and normal-risk Patients
The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center
More information30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More informationTAVR: Review of the Robust Data from Randomized Trials
TAVR: Review of the Robust Data from Randomized Trials Nicholas J. Ruggiero II, MD,FACP, FACC, FSCAI, FSVM, FCPP Director, Structural Heart Disease and Non-Coronary Interventions Director, Jefferson Heart
More informationStainless Steel. Cobalt-chromium
Sapien is better than Corevalve! Raj R. Makkar, MD Associate Director, Cedars-Sinai Heart Institute Associate Professor, UCLA School of Medicine, Los Angeles Eberhard Grube: Pioneer in the field of TAVR
More informationTAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationClinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients
Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients Susheel Kodali, MD on behalf of The PARTNER Trial Investigators
More informationEvolving and Expanding Indications for TAVR
Evolving and Expanding Indications for TAVR Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationTAVI limitations for low risk patients
TAVI limitations for low risk patients Dr. T. Modine / P. Lancellotti MD, PhD, MBA CHRU de Lille, France Potential conflicts of interest Speaker's name: Thomas Modine I have the following potential conflicts
More informationVinod H. Thourani, MD, FACC, FACS
Considering SAVR in the TAVR era: Surgical Implications of TAVR Vinod H. Thourani, MD, FACC, FACS Professor of Cardiothoracic Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationIs TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients?
Is TAVI ready for prime time in: - Intermediate risk patients? - Low risk patients? Didier TCHETCHE, MD. Clinique PASTEUR, Toulouse, France, Conflicts of interest: -Consultant for Edwards LifeSciences
More informationAortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
More informationAortic Stenosis in the Elderly: Difficulties for the Clinician. Are Symptoms Due to Aortic Stenosis?
Aortic Stenosis in the Elderly: Difficulties for the Clinician Are Symptoms Due to Aortic Stenosis? Raphael Rosenhek Department of Cardiology Medical University of Vienna No disclosure European Society
More informationTAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con
TAVR 2018: TAVR has high clinical efficacy according to baseline patient risk! ii. Con Dimitrios C. Angouras, MD, FETCS Associate Professor of Cardiac Surgery National and Kapodistrian University of Athens,
More informationValve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.
Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Professor, Thoracic and Cardiovascular Surgery University of Florida klodell@surgery.ufl.edu Disclosures
More informationTAVR in 2017 What we know? What to expect?
Journal of Geriatric Cardiology (2018) 15: 55 60 2018 JGC All rights reserved; www.jgc301.com Perspective Open Access TAVR in 2017 What we know? What to expect? Panagiota Kourkoveli 1,*, Konstantinos Spargias
More informationTranscatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van
More informationTHE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON
THE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON INTRODUCTION History of heart valve intervention Current indications
More informationAlec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France
Future Percutaneous Therapies for Mitral Valve Disease (Mitraclip,percutaneous annuloplasty and transcatheter valve implantation) Will they reach the TAVI s success? Alec Vahanian,FESC, FRCP (Edin.) Bichat
More informationCardiolucca Heart Celebration. Seconda generazione delle valvole e miglioramento degli outcome nel trattamento percutaneo della stenosi aortica
Cardiolucca 2014 Heart Celebration Seconda generazione delle valvole e miglioramento degli outcome nel trattamento percutaneo della stenosi aortica Sergio Berti Ospedale del Cuore Fondazione C.N.R. Reg.
More informationResults of Transfemoral Transcatheter Aortic Valve Implantation
Results of Transfemoral Transcatheter Aortic Valve Implantation Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationPARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients
O P E N A C C E S S Department of Cardiology, Aswan Heart Centre *Email: ahmed.elguindy@aswanheartcentre.com Lessons from the trials PARTNER 2A & SAPIEN 3: TAVI for intermediate risk patients Ahmed ElGuindy*
More informationCurrent Evidence in TAVI patients using ACURATE and LOTUS valves
Current Evidence in TAVI patients using ACURATE and LOTUS valves Giuseppe Tarantini, MD, PhD, FESC, Professor and Director of Interventional Cardiology University of Padua GISE President Potential conflicts
More informationTranscatheter Aortic Valve Implantation Present Status and Perspectives
Transcatheter Aortic Valve Implantation Present Status and Perspectives Angioplasty Summit TCTAP 2010 Alain Cribier, MD University of Rouen, France Transcatheter Aortic Valve Implantation has entered the
More informationStructural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)
Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR) Kathleen Harper DO FACC FACP 87 Chief, Cardiology Section VA Maine Healthcare Kathleen.Harper@va.gov Prevalence of Aortic Stenosis
More information3 years after introduction of TAVI in QEH. Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong
3 years after introduction of TAVI in QEH Michael KY Lee On Behalf of QEH TAVI Heart Team Queen Elizabeth Hospital Hong Kong HA Convention 2014 Introduction Aortic Stenosis most common valvular heart disease
More informationTranscatheter aortic valve implantation and pre-procedural risk assesment
Transcatheter aortic valve implantation and pre-procedural risk assesment Alec Vahanian,FESC, FRCP(Edin.) Bichat Hospital University Paris VII, Paris, France Disclosures Relationship with companies who
More informationFive-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
More informationTranscatheter aortic valve implantation for severe aortic valve stenosis with the ACURATE neo2 valve system: 30-day safety and performance outcomes
All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions
More informationTAVR for Complex Aortic Valvular Conditions
TAVR for Complex Aortic Valvular Conditions Wilson Y. Szeto, MD Professor of Surgery Chief, Cardiovascular Surgery at Penn Presbyterian Surgical Director, Transcatheter Cardio-Aortic Therapies Associate
More informationEdwards Lifesciences 2011 Investor Conference 12/9/2011
Edwards Lifesciences 2011 Investor Conference EDWARDS LIFESCIENCES Transcatheter Heart Valves Larry L. Wood Corporate Vice President, Transcatheter Valve Replacement 2 1 Edwards Lifesciences 2011 Investor
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationProgress In Transcatheter Aortic Valve Implantation
Progress In Transcatheter Aortic Valve Implantation Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia 4 th APCASH 8 th Sept 2013 Disclosure Statement
More informationThe Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives. Martin B. Leon, MD
The Changing Epidemiology of Valvular Heart Disease: Implications for Interventional Treatment Alternatives Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New
More informationEstablishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS
Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationMeasuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France
Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France Faculty disclosure Bernard Iung I disclose the following financial relationships: Consultant
More informationComplicanze durante TAVI. Brambilla Nedy IRCCS Policlinico San Donato
Complicanze durante TAVI Brambilla Nedy IRCCS Policlinico San Donato 0 2 4 6 9 11 14 16 22 26 31 33 37 43 52 61 69 78 87 93 106 113 121 151 171 186 201 225 267 283 294 311 349 502 515 709 1007 Number of
More informationThe Future of Medicine. Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy
The Future of Medicine Who to TAVR? Azeem Latib MD EMO-GVM Centro Cuore Columbus and San Raffaele Scientific Institute, Milan, Italy FIRST PATIENT TO UNDERGO PTCA FIRST PATIENT TO UNDERGO TAVI Grüntzig
More informationTAVI: Transapical Procedures
Cardiology Update Davos TAVI: Transapical Procedures Volkmar Falk, MD University Hospital Zürich TA-AVI: antegrade, simple, safe The front door approach! Transapical TAVI Technical advantages of TA approach
More informationResults of Transapical Valves. A.P. Kappetein Dept Cardio-thoracic surgery
Results of Transapical Valves A.P. Kappetein Dept Cardio-thoracic surgery Rotterda am, The Netherlands 2002 FIM 2003 2005 2006 2010 THV THV Cribier-Edwards Edwards Edwards Sapien Sapien XT Bovine pericardium
More informationParavalvular Regurgitation is a Risk Factor Following TAVI
Paravalvular Regurgitation is a Risk Factor Following TAVI Philippe Pibarot, DVM, PhD, FACC, FESC, FASE Canada Research Chair in Valvular Heart Disease INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE
More informationAustralia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes
Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia
Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II
More information> 1200 Patients
> 1200 Patients 2002-2008 2008 Transfemoral (n=628) Transapical (n=457) Antegrade N=59 Retrograde N=569 TRAVERCE n=172 RECAST n = 24 REVIVE II n = 106 REVIVAL II n =40 Early First in Man irevive n = 22
More informationProf. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation
Prof. Dr. Thomas Walther TAVI in ascending aorta / aortic root dilatation nn AorticStenosis - Guidelines TAVI and aortic aneurysm? Few data published. EJCTS 2014;46:228-33 TAVI and aortic aneurysm? Few
More informationSAPIEN 3 Sizing Considerations:
SAPIEN 3 Sizing Considerations: Oversizing, Undersizing, or Volume reduction? John Webb MD St Paul s Hospital University of British Columbia Vancouver Disclosure Statement of Financial Interest Within
More informationThe Impact of TAVI Nurse Coordinator on patient management of Transcatheter Aortic Valve Implantation (TAVI) program in QEH
HA Convention 18-19 May 2015 The Impact of TAVI Nurse Coordinator on patient management of Transcatheter Aortic Valve Implantation (TAVI) program in QEH Division of Cardiology Department of Medicine Queen
More informationValvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD
Valvular Heart Disease Transcatheter Valve Therapies October 2016 Brian Whisenant MD Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationNext Generation Therapies: Aortic, Mitral and Beyond
Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:
More information